ID   Tango GPCR-bla U2OS
AC   CVCL_ZJ93
SY   Tango GPCR U2OS
DR   Wikidata; Q98133124
RX   PubMed=19726785;
CC   Population: Caucasian.
CC   Characteristics: This is the parental cell line for all other ThermoFisher Tango cell lines. It is not distributed.
CC   Characteristics: Stably expresses a beta-arrestin/TEV protease fusion protein and a beta-lactamase reporter gene under the control of an upstream activator sequence (UAS).
CC   Sequence variation: Mutation; HGNC; HGNC:9277; PPM1D; Simple; p.Arg458Ter (c.1372C>T); ClinVar=VCV002445214; Zygosity=Heterozygous (from parent cell line).
CC   Genetic integration: Method=Transfection/transduction; Gene=HGNC; HGNC:712; ARRB2.
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P62593; Escherichia coli beta-lactamase bla (Note=With p.Met1_Phe22del, p.Ala23Met, p.Val82Ile and p.Met184Val).
CC   Genetic integration: Method=Transfection/transduction; Gene=UniProtKB; P04517; Tobacco etch virus (TEV) protease (Note=AA 2038-2279).
CC   Derived from site: In situ; Bone, tibia; UBERON=UBERON_0000979.
DI   NCIt; C9145; Osteosarcoma
DI   ORDO; Orphanet_668; Osteosarcoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0042 ! U2OS
SX   Female
AG   15Y
CA   Cancer cell line
DT   Created: 02-07-20; Last updated: 10-04-25; Version: 10
CH   CVCL_ZK27 ! T-REx Tango GHSR-bla U2OS
CH   CVCL_ZK28 ! T-REx Tango P2RY14-bla U2OS
CH   CVCL_ZK53 ! Tango ADORA1-bla U2OS
CH   CVCL_ZJ94 ! Tango ADORA3-bla U2OS
CH   CVCL_ZJ95 ! Tango ADRA2A-bla U2OS
CH   CVCL_ZJ96 ! Tango AGTR1-bla U2OS
CH   CVCL_ZJ97 ! Tango AGTRL1-bla U2OS
CH   CVCL_ZJ98 ! Tango CCR1-bla U2OS
CH   CVCL_ZJ99 ! Tango CCR2-bla U2OS
CH   CVCL_ZK00 ! Tango CCR3-bla U2OS
CH   CVCL_ZK01 ! Tango CCR4-bla U2OS
CH   CVCL_ZK02 ! Tango CCR5-bla U2OS
CH   CVCL_ZK03 ! Tango CCR6-bla U2OS
CH   CVCL_ZK04 ! Tango CCR7-bla U2OS
CH   CVCL_ZK05 ! Tango CHRM2-bla U2OS
CH   CVCL_ZK06 ! Tango CMKLR1-bla U2OS
CH   CVCL_ZK07 ! Tango CNR1-bla U2OS
CH   CVCL_ZK08 ! Tango CNR2-bla U2OS
CH   CVCL_ZK09 ! Tango CXCR1-bla U2OS
CH   CVCL_ZK10 ! Tango CXCR2-bla U2OS
CH   CVCL_ZK11 ! Tango CXCR3-bla U2OS
CH   CVCL_ZK12 ! Tango CXCR4-bla U2OS
CH   CVCL_ZK13 ! Tango CXCR6-bla U2OS
CH   CVCL_ZK14 ! Tango CXCR7-bla U2OS
CH   CVCL_ZK15 ! Tango DRD1-bla U2OS
CH   CVCL_ZK16 ! Tango EDG1-bla U2OS
CH   CVCL_ZK17 ! Tango EDG2-bla U2OS
CH   CVCL_ZK18 ! Tango EDG3-bla U2OS
CH   CVCL_ZK37 ! Tango EDG4-bla U2OS
CH   CVCL_ZK38 ! Tango EDG5-bla U2OS
CH   CVCL_ZK30 ! Tango EDG6-bla U2OS
CH   CVCL_ZK32 ! Tango EDG7-bla U2OS
CH   CVCL_ZK33 ! Tango EDG8-bla U2OS
CH   CVCL_ZL09 ! Tango F2RL1-bla U2OS
CH   CVCL_ZL03 ! Tango GALR2-bla U2OS
CH   CVCL_ZK95 ! Tango GLP2R-bla U2OS
CH   CVCL_ZL12 ! Tango GPR1-bla U2OS
CH   CVCL_ZL11 ! Tango GPR109A-bla U2OS
CH   CVCL_ZL13 ! Tango GPR119-bla U2OS
CH   CVCL_ZK31 ! Tango GPR120-bla U2OS
CH   CVCL_ZK34 ! Tango GPR23-bla U2OS
CH   CVCL_ZL10 ! Tango GPR35-bla U2OS
CH   CVCL_ZL14 ! Tango GPR44 (CRTH2)-bla U2OS
CH   CVCL_ZK29 ! Tango GPR8-bla U2OS
CH   CVCL_ZK36 ! Tango GPR87-bla U2OS
CH   CVCL_ZK35 ! Tango GPR92-bla U2OS
CH   CVCL_ZL06 ! Tango HTR1A-bla U2OS
CH   CVCL_ZK94 ! Tango HTR1D-bla U2OS
CH   CVCL_ZK96 ! Tango HTR2A-bla U2OS
CH   CVCL_ZL05 ! Tango M1-bla U2OS
CH   CVCL_ZL04 ! Tango M4-bla U2OS
CH   CVCL_ZL00 ! Tango MTNR1B-bla U2OS
CH   CVCL_ZL02 ! Tango NPY1R-bla U2OS
CH   CVCL_ZK92 ! Tango NPY2R-bla U2OS
CH   CVCL_ZL01 ! Tango NPY5R-bla U2OS
CH   CVCL_ZL07 ! Tango OPRD1-bla U2OS
CH   CVCL_ZK97 ! Tango OPRK1-bla U2OS
CH   CVCL_ZL08 ! Tango OPRL1-bla U2OS
CH   CVCL_ZK93 ! Tango OPRM1-bla U2OS
CH   CVCL_ZK19 ! Tango PTAFR-bla U2OS
CH   CVCL_ZK20 ! Tango RLN3R1-bla U2OS
CH   CVCL_ZK21 ! Tango SSTR1-bla U2OS
CH   CVCL_ZK22 ! Tango SSTR2-bla U2OS
CH   CVCL_ZK23 ! Tango SSTR5-bla U2OS
CH   CVCL_ZK24 ! Tango TACR1-bla U2OS
CH   CVCL_ZK25 ! Tango TACR3-bla U2OS
CH   CVCL_ZK26 ! Tango TBXA2R-bla U2OS
//
RX   PubMed=19726785; DOI=10.1177/1087057109343809;
RA   Wetter, Justin A.
RA   Revankar, Chetana
RA   Hanson, Bonnie J.
RT   "Utilization of the Tango beta-arrestin recruitment technology for
RT   cell-based EDG receptor assay development and interrogation.";
RL   J. Biomol. Screen. 14:1134-1141(2009).
//